Next Phase Newsletter

A life sciences Venture Capital firm based in Toronto with other offices throughout USA and Canada manages over $350M and is currently investing from a recently closed new fund. The firm typically makes initial investments ranging from $2-6 million of equity and looks to invest $8-12 million over the lifetime of the investment. The firm expects to make 4-6 investments over the next 12 months.

The firm invests primarily in therapeutics and medical devices, with selective investments in diagnostic imaging and digital health. The firm generally looks for companies phase I and later that have at least some human proof-of-concept with either early human efficacy signs or very strong animal data coupled with human safety data.

The firm invests in companies throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage venture capital firm based in the bay area is currently making Seed and Series A investments into companies ranging from $500K to $7 million, depending on the stage and financial requirements of the company – with up to $15 million over the company’s lifetime. The firm has a preference for companies based in Silicon Valley, but will consider opportunities globally.

The firm is sector agnostic having its main screening criteria be that the company is operating in a white space (meaning little or no competition) and having potential market sizes of at least $10 billion from a bottoms-up view. That being said, companies in the life science space that the firm is most interested in include medical technology, devices, and diagnostics for massive unmet markets such as diabetes, hypertension, and obesity. Additionally, the firm is interested in lab and provider service companies, although the firm is very sensitive to market size (need to meet the aforementioned market size). Areas where the firm has been involved previously include a genomic cardiovascular diagnostic, bioinformatics, lab services and other diagnostics companies.

The firm looks to be the first institutional investor in companies and acts as a lead or co-lead investor. The firm looks to take an active board seat into companies and assist with many aspects of the company’s development. The firm considers experienced management teams and a history of success as a strong plus, but is comfortable in working with first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life-sciences focused venture capital firm is currently making investments out of its third fund. The firm primarily makes equity investment into seed and early stage rounds ranging from $250,000 to $1 million initially and up to $2 million over the lifetime of the investment. The firm is focused on companies located in Southern California and the Southwestern United States although they are open to review companies from throughout the US. The firm could make as many as 3 new investments over the next 6-9 months.

The firm is looking for companies in sectors of Therapeutics, Diagnostics, Medical Devices, Life Science Tools and Healthcare IT. The firm is agnostic in terms of subsectors and indications within these areas and is also interested in orphan indications and wireless medical devices. The firm looks to invest in early-stage companies including pre-clinical stage companies with some supporting in-animal data, although it is not a requirement.

The firm is looking for privately held companies with experienced management teams. The firm looks to play an active role as an investor and generally looks to take a board or board observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in New York, NY looks to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm prefers companies that have some proof of concept data, with some animal studies complete, and will invest through to clinical-stage companies. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.

The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.

The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with multiple offices throughout the USA currently has approximately $350 million in total assets under management. The firm is making 2-3 new investments every month from its newest fund. The firm typically makes investments ranging from $0.25 million to $6 million over the life of the company. The firm prefers to invest early at the Seed, Series A and Series B stage. The firm will consider investing in any industry segment, but there must be at least one other venture capital firm making their first investment in the company in this round. The firm only invests in US-based companies.

The firm is currently looking for new investment opportunities in the life sciences space. The firm is very opportunistic in terms of sectors, subsectors and indications. The firm is currently active in therapeutics companies that develop nucleic acid drugs and small molecules to treat oncology and infectious diseases. The firm is also active in medical devices companies that develop active diagnostic and therapeutic radiation devices, implantable devices and surgical devices.

The firm seeks to invest in private companies based in US and only acts as a co-investor in financing rounds. The firm invests in companies that already have at least one other venture capital firm making their first investment. The best time to engage with the firm is when a company has a term sheet or expression of interest from another Venture Capital Firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A single family office based in New York, NY. The group has significant experience in the healthcare space and has made several successful investments in a variety of life science companies. Initial investments can range widely depending on the needs and stage of development of the company, with allocations from $100K – $4M. Investments may come in the form of straight equity or convertible notes. The firm may lead or co-invest in a syndicate and typically looks to take a meaningful stake in portfolio companies. The group may seek a board seat depending on the size of the investment and their role in the financing round, however it is not a requirement.

The firm is fairly opportunistic in the healthcare space and is interested in therapeutics, medical devices and increasingly digital health/healthcare IT, however the group favors breakthrough technologies. As for therapeutics, The firm is most interested in companies with POC/Ph. II data, but will evaluate companies with some earlier clinical data as well. In the medical device space, the group will consider companies yet to obtain FDA approval, but looks for companies with a clear path to approval and commercialization. The firm has historically focused on biotech and medtech companies, but plans to become more active in the healthcare IT space going forward.

The firm has no strict management team requirements, but favors strong management teams with considerable experience. The group tends to focus on U.S.-based companies, but has no geographic restrictions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.